Loading...
Treatment options for advanced hepatocellular cancer (HCC) have expanded to include tyrosine kinase inhibitors, immune checkpoint inhibitors, and anti-angiogenesis agents. In a recent phase II trial (Ann Oncol 2017; 28: 528), clinical activity against HCC was demonstrated by cabozantinib, a tyrosine kinase inhibitor targeting MET, VEGF, and AXL, which are associated with HCC progression and resistance to standard first-line therapy with sorafenib.
Investigators now report results of an industry-sponsored, international, randomized, double-blind, placebo-controlled trial (CELESTIAL) that compared cabozantinib versus placebo in 707 patients with HCC, Child-Pugh A liver function, prior treatment with sorafenib, and 1 to 2 prior systemic regimen…